@article{ATM25637,
author = {Rupak Desai and Upenkumar Patel and Hemant Goyal and Afrina Hossain Rimu and Dipen Zalavadia and Pardeep Bansal and Nihar Shah},
title = {In-hospital outcomes of inflammatory bowel disease in cannabis users: a nationwide propensity-matched analysis in the United States},
journal = {Annals of Translational Medicine},
volume = {7},
number = {12},
year = {2019},
keywords = {},
abstract = {Background: Literature suggests the role of cannabis (marijuana) as an anti-inflammatory agent. However, the impact of recreational marijuana usage on in-hospital outcomes of inflammatory bowel disease (IBD) remains indistinct. We assessed the outcomes of Crohn’s disease (CD) as well as ulcerative colitis (UC) with vs. without recreational marijuana usage using a nationally illustrative propensity-matched sample.
Methods: The Nationwide Inpatient Sample datasets (2010–2014) were queried to identify adults with CD and UC hospitalizations with cannabis use and linked complications using ICD-9 CM codes. Categorical and continuous variables were compared between propensity-matched cohorts using Chi-square and Student’s t-test, respectively. Primary endpoints were in-hospital complications, whereas secondary endpoints were the discharge disposition, mean length of stay (LOS) and hospital charges.
Results: Propensity-matched cohorts included 6,002 CD (2,999 cannabis users & 3,003 non-users) and 1,481 UC (742 cannabis users & 739 non-users) hospitalizations. In CD patients, prevalence of colorectal cancer (0.3% vs. 1.2%, P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25637}
}